[Methoxy polyethylene glycol-epoetin beta (Mircera) in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins].
Dávila Fajardo
C L
CL
Peña Ortega
M
M
Cabeza Barrera
J
J
Prados Garrido
M D
MD
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000517:prevention & control; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced* / Q000517:prevention & control; D007279:Injections, Subcutaneous; D007674:Kidney Diseases / Q000097:blood / Q000150:complications*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; C508420:continuous erythropoietin receptor activator; C103998:epoetin beta; D004921:Erythropoietin; D011092:Polyethylene Glycols